DGAP-News: 4SC AG: Stifel Nicolaus Europe initiates research coverage on 4SC with a buy rating

Stifel Nicolaus Europe initiates research coverage on 4SC with a buy rating
 

Planegg-Martinsried, Germany, 18 July 2018 - Stifel Nicolaus Europe Limited, London, UK (Stifel Europe) have initiated research coverage on 4SC AG (4SC, FSE Prime Standard: VSC). In their recently published report, Stifel Europe's independent analysts have initiated coverage with a buy rating.

In addition to Stifel Europe, 4SC is also covered by LifeSci Capital LLC, New York, USA, goetzpartners securities Limited, London, UK, and Edison Investment Research Limited, London, UK.

Institutional investors can obtain a copy of the research report directly from the analyst at Stifel Europe by contacting James Mainwaring at james.mainwaring@stifel.com. Publicly accessible research on 4SC can be downloaded from 4SC's website in the "Investors & Media" section.

- Press release ends -

Further information

About Stifel Nicolaus Europe Limited (Stifel Europe)

Stifel Europe is a leading full-service investment bank, based in London. Wholly owned by U.S. listed Stifel Financial Corp., Stifel Europe provides a bulge bracket range of services to middle-market clients including corporate broking, equity capital markets, debt capital markets and mergers & acquisitions practices.

Stifel Europe offers institutional investors differentiated, research-driven equity products with a dedication to value and service. Stifel Europe manages public offerings of equity and debt securities, raises debt and equity in the private markets, and initiates, structures, and negotiates mergers, acquisitions, and divestitures.

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life.

4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises three key drug candidates in various stages of preclinical and clinical development: resminostat, domatinostat (4SC-202) and 4SC-208.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 31 March 2018 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

Important note

The sole responsibility for the content and the conclusions of the mentioned analyst studies rests with the respective authors. Banks and securities firms use different terms for their equity ratings. Any opinions, estimates or forecasts made by these analysts on the performance of 4SC are not opinions, forecasts or predictions of 4SC or its management.

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact

Anna Niedl, Ph.D., CIRO
Corporate Communications & Investor Relations
anna.niedl@4sc.com
+49 89 700763-66